Every 8-K that Revvity, Inc. (RVTY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RVTY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVTY filings page.
Revvity, Inc. reported second-quarter 2026 results and outlined plans to divest its China Immunodiagnostics business. Revenue was $730 million, up from $720 million a year earlier, with GAAP earnings per share from continuing operations of $0.48 versus $0.47. Adjusted EPS from continuing operations rose to $1.41 from $1.18, and adjusted operating profit margin increased to 28.9% from 26.6%. GAAP operating income was $89 million, including $16 million of tariff-related refunds.
On a pro forma basis excluding the China Immunodiagnostics business (China IDX), revenue was $711 million with 4% pro forma revenue growth and 3% pro forma organic revenue growth. Diagnostics grew strongly while Life Sciences declined modestly. The company entered a definitive agreement to sell China IDX, which represented approximately 6% of 2025 revenue, for up to $200 million, subject to adjustments and closing conditions, and expects the transaction to close by the end of 2027. Pro forma adjusted EPS for 2026 is guided to $5.30–$5.40 on pro forma revenue of $2.83–$2.86 billion; operating cash flow from continuing operations for the first half of 2026 was $317.8 million.
Revvity, Inc. reported higher first quarter 2026 results and outlined plans to divest its China Immunodiagnostics business. Revenue rose to $711 million from $665 million, a 7% increase, with 3% organic growth. GAAP EPS from continuing operations was $0.37, up from $0.35, while adjusted EPS reached $1.06 versus $1.01 a year earlier. Pro forma revenue excluding the China Immunodiagnostics business was $687 million, with pro forma organic growth of 6%.
The company signed a letter of intent to sell the China Immunodiagnostics business, which represented about 6% of 2025 revenue, for up to $200 million, with closing targeted for 2027 subject to conditions and approvals. On a pro forma basis, Q1 GAAP EPS from continuing operations was $0.40 and adjusted EPS was $1.04. Revvity now forecasts full year 2026 pro forma revenue of $2.81–$2.84 billion, pro forma organic revenue growth of 3%–4%, and pro forma adjusted EPS of $5.20–$5.30.
Revvity, Inc. reported results of its annual shareholder meeting and a governance change. Shareholders approved an amendment to the Amended and Restated By-laws to allow shareholders owning 25% of the company’s common stock to call a special meeting, effective April 28, 2026.
All ten director nominees were elected, each receiving over 90 million votes in favor. Shareholders also ratified Deloitte & Touche LLP as independent auditor, approved on an advisory basis the company’s executive compensation, and backed the new special meeting right. A shareholder proposal on executive stock ownership was rejected, with 22,974,850 votes for and 76,502,157 against.
Revvity, Inc. furnished an update on its performance by announcing financial results for the fourth quarter and full fiscal year ended December 28, 2025. The company released these results through a press release dated February 2, 2026, which is provided as Exhibit 99.1 and treated as furnished, not filed, under securities law.
Revvity, Inc. filed a current report describing upcoming financial communications and an investor presentation. The company announced preliminary expectations for certain financial results for its fourth quarter ended December 28, 2025 and said it will release full fourth quarter and full year 2025 financial results on February 2, 2026. These details are contained in a press release furnished as an exhibit.
The filing also notes that President and CEO Dr. Prahlad Singh is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with the presentation materials furnished as a separate exhibit. Both the press release and the presentation are being furnished rather than filed, which limits their exposure to certain Exchange Act liabilities.
Revvity, Inc. filed a current report stating that it announced its financial results for the third quarter ended September 28, 2025. The company released these quarterly results through a press release dated October 27, 2025, which is furnished as Exhibit 99.1.
The report clarifies that the press release is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings unless specifically referenced. The filing is signed by Senior Vice President and Chief Financial Officer Maxwell Krakowiak.
Revvity (RVTY) appointed Anita Gonzales as Vice President and Chief Accounting Officer, effective October 23, 2025. Gonzales has served as the company’s Vice President and Controller since May 2023, after joining in March 2021 to lead integration and controllership initiatives. She previously spent a decade at General Electric in corporate audit and GE Aviation leadership roles, and earlier advanced to Senior Manager at PwC. Gonzales holds MPA and BBA degrees from the University of Texas at Austin and is a CPA.